Zambia’s cancer research output is growing, but the gaps are still wide
Zambia’s cancer research base has expanded over the past decade, yet the portfolio remains uneven and heavily weighted toward late-stage clinical problems rather than prevention, palliation, or health economics. A national mapping study examined 76 Zambian cancer papers published between 2012 and 2022 and paired the evidence review with a modified consensus meeting in Ndola involving 31 domestic and international stakeholders. The result is a detailed picture of where inquiry has matured and where the country is still operating with too little data to guide planning.
The central concern is straightforward: cancer incidence is rising, mortality remains high because patients often present late, and the research agenda has not fully caught up with the scale of the problem. In that setting, research capacity is not an academic luxury. It is a core part of cancer control, especially when policy makers need locally generated evidence to choose screening strategies, assign resources, and measure whether interventions are reaching the right patients.
Cervical cancer dominates the evidence base while other priorities remain thinly studied
The literature reviewed across Zambia was broader than before and no longer confined to a single disease site, but cervical cancer still dominated the national research conversation. Delay in deciding to seek care was the most frequently studied topic, appearing in 17 papers and accounting for 63.0% of the delay-related work, with much of that attention centered on cervical cancer. This pattern is clinically revealing. When research repeatedly returns to late presentation, it usually reflects a health system in which barriers to awareness, referral, diagnosis, and access remain unresolved.
The imbalance becomes sharper when the study designs are considered. Most of the research was retrospective: 47 of 76 studies, or 61.8%, used that approach. Only one randomized controlled trial was identified. That matters because retrospective studies can describe burden and patterns of care, but they rarely test whether a new intervention changes outcomes. For a country trying to strengthen cancer control, the scarcity of interventional research limits what can be concluded about screening models, treatment pathways, or support services.
Prevention, palliative care, and health economic studies were notably lacking. Each of those domains fills a different clinical gap. Prevention determines whether disease burden can be reduced before patients ever reach oncology units. Palliative care shapes quality of life when cure is no longer realistic. Health economics informs whether any proposed strategy can be sustained in a constrained health system. Without those layers of evidence, planning can overemphasize diagnosis and treatment while neglecting the services that determine whether patients survive and how they live.
International funding dominates, and local authorship remains limited
The funding profile points to another structural weakness. More than 90% of the 11 most prolific funders were international, and they were predominantly based in the United States and the United Kingdom. External support is valuable and often necessary, but a research ecosystem that relies so heavily on outside financing can struggle to set its own agenda, retain expertise, and build long-term national ownership.
Authorship patterns echoed the same imbalance. Zambian researchers were first authors on 33 of 76 studies, or 43%, and last authors on 34 of 76 studies, or 45%. Those proportions show participation, but not full control over the research enterprise. In many biomedical settings, first and last authorship are markers of intellectual leadership and project direction. Lower representation in those positions suggests that important parts of the national evidence base may still be designed, funded, or interpreted without sufficient local leadership.
This is not merely an academic concern. When research questions are shaped outside the country, they may miss the clinical realities that matter most at district and referral levels—transport barriers, diagnostic delays, specimen handling, workforce shortages, or the practical feasibility of follow-up. Those are exactly the issues that determine whether a screening or treatment program can work outside a pilot setting.
The cervical cancer registry and digital collaboration offer a practical platform
The mapping exercise did not identify only deficits. It also found features that can be leveraged to expand capacity. The existing national cervical cancer registry, active global collaboration, and adoption of technology emerged as facilitators. Each one can serve a different function in the research pipeline. A registry creates a foundation for surveillance and longitudinal tracking. International collaboration can provide mentorship, statistical support, and access to multicenter methods. Technology can improve data capture, communication, and coordination across institutions.
Those assets are especially important because Zambia’s cancer burden requires research that moves beyond description. Better registry data can support incidence estimates and service planning. Digital tools can make multicenter studies more realistic. Collaborative networks can help investigators move from retrospective chart reviews toward prospective cohorts, implementation studies, and trials that test whether local interventions actually improve care.
The consensus meeting in Ndola was built around these kinds of gaps and enabling factors. Thirty-one stakeholders co-developed priorities and strategies, an approach that is essential when research planning must serve a national cancer control strategy rather than a single department or institution. The value of such a meeting lies in translation: evidence on its own does not reorganize services unless researchers, clinicians, administrators, and policy leaders agree on what should happen next.
Capacity building must be sustained at individual, institutional, and national levels
The study’s conclusion is anchored in a simple but demanding proposition: strengthening cancer research in Zambia will require sustained commitment to co-developed priorities across individual, organizational, and institutional levels. Researchers need training and mentorship. Institutions need systems that support data quality, ethics review, collaboration, and protected research time. National leaders need to align funding, governance, and evaluation with the priorities identified through the mapping exercise.
In practical terms, this means shifting away from a research culture dominated by retrospective observation and toward one that can generate evidence for prevention, palliation, and cost-conscious service delivery. It also means supporting Zambian investigators so they are not only contributing to studies, but leading them. Local authorship is not a symbolic metric; it is a proxy for who defines the questions and who owns the answers.
The study leaves a clear operational challenge for cancer control in Zambia. The country now has a map of what has been studied, what has been missed, and where the research system still depends too heavily on outside resources. The next step is not another description of the gap. It is the harder work of building the infrastructure and leadership needed to close it.